Jove
Visualize
Contact Us

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.8K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.8K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

466
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
466
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.4K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.4K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

589
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
589

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gradient of CD79B expression in diffuse large B-cell lymphoma corresponds to stages of germinal center B-cell differentiation.

Haematologica·2026
Same author

Association of ideal body weight-normalized post-transplantation cyclophosphamide dose with chronic GVHD in patients with overweight/obesity.

Bone marrow transplantation·2026
Same author

Efficacy and relapse profiles of Pola-R-CHP versus R-CHOP in previously untreated diffuse large B-cell lymphoma: A multicentre real-world study.

British journal of haematology·2025
Same author

Late-Onset Invasive Aspergillosis With Pituitary Involvement and Dysfunction Following CD19 Chimeric Antigen Receptor T-Cell Therapy.

EJHaem·2025
Same author

Central compartment of nasal cavity-derived MMP-9 enhances mixed-type 2 inflammation in eosinophilic chronic rhinosinusitis.

International immunology·2025
Same author

[Successful treatment with fostamatinib and thrombopoietin receptor agonists in immune thrombocytopenia].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2025
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Apr 4, 2026

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
05:31

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

6.4K

Dexrazoxane reduces antithrombin activity: a case series.

Tomohiro Nagano1,2, Kaho Makiuchi1,2, Akifumi Matsumura1,2

  • 1Department of Hematology, Japanese Red Cross Okayama Hospital, Okayama, Japan.

International Cancer Conference Journal
|April 3, 2026
PubMed
Summary
This summary is machine-generated.

Dexrazoxane may lower antithrombin activity, potentially increasing thrombosis risk in patients receiving chemotherapy. Monitoring antithrombin levels and thrombosis is recommended during dexrazoxane treatment.

Keywords:
AnthracyclineAntithrombinCase seriesDexrazoxaneExtravasationThrombosis

More Related Videos

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.5K
A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
10:26

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Published on: June 2, 2015

18.1K

Related Experiment Videos

Last Updated: Apr 4, 2026

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
05:31

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

6.4K
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.5K
A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
10:26

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis

Published on: June 2, 2015

18.1K

Area of Science:

  • Oncology
  • Pharmacology
  • Hematology

Background:

  • Dexrazoxane is used to prevent anthracycline-induced cardiotoxicity and treat extravasation.
  • Thrombosis is not a common adverse effect but has been suggested as a potential risk.
  • Anthracycline extravasation is a serious complication during chemotherapy.

Purpose of the Study:

  • To investigate the potential association between dexrazoxane administration and decreased antithrombin activity.
  • To explore the link between reduced antithrombin activity and thrombosis development.
  • To raise awareness among clinicians regarding potential dexrazoxane-related adverse effects.

Main Methods:

  • Case series presentation of three patients (four episodes) who received dexrazoxane.
  • Monitoring of antithrombin activity levels following dexrazoxane administration.
  • Review of previous reports on dexrazoxane and thrombosis.

Main Results:

  • All three patients showed decreased antithrombin activity after dexrazoxane administration.
  • Antithrombin activity reduction occurred a median of 4 days post-injection and recovered later.
  • One patient developed deep-vein thrombosis, with no other apparent cause than dexrazoxane.

Conclusions:

  • Dexrazoxane may be associated with a decline in antithrombin activity.
  • This decrease in antithrombin activity could potentially contribute to thrombosis.
  • Clinicians should monitor antithrombin levels and watch for thrombosis in patients on dexrazoxane.